Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer

Gastric Cancer Clinical Trial

Official title:

Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer: A Randomized, Parallel, Controlled Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02537171
• Other study ID #: AHEAD-G303
• Status: Recruiting
• Phase: Phase 3
• First received: July 13, 2015
• Last updated: August 1, 2016
• Start date: July 2015
• Est. completion date: October 2016

Study information

• Verified date: August 2015
• Source: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
• Contact: Xu jianming, M.D.
• Phone: +861066947178
• Email: jmxu2003[@]yahoo.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The study is to evaluate the efficacy of Apatinib in patients with advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction.

Description:

The study is to investigate the efficacy of Apatinib as maintenance therapy after first fine treatment in patients with advanced or metastatic adenocarcinoma of stomach or gastroesophageal junction through progression-free survival(PFS). Apatinib will be given to patients who have received first-line chemotherapy with an efficacy assessment of stable disease(SD), complete response(CR), or partial response(PR) after 4 cycles. Patients were randomly assigned to 750mg group or 500mg group continually until disease progression or intolerable toxicity or patients withdrawal of consent, and the sample size is 40 individuals.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: October 2016
• Est. primary completion date: August 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age=18 years;

2. Pathologically diagnosed with advanced gastric adenocarcinoma (including gastroesophageal junction) with measurable metastases outside the stomach (=10mm on spiral CT scan, and meet the criteria of Response Evaluation Criteria in Solid Tumors 1.1);

3. Locally advanced, recurrent or metastatic gastric or gastro-oesophageal junction adenocarcinoma;

4. Finished first-line chemotherapy (fluorouracil combined with oxaliplatin, cisplatin, paclitaxel or docetaxel) 3 weeks a cycle for 4 cycles, of which the last efficacy assessment is SD, PR or CR. No more than 28 days from the starting day of last cycle of chemotherapy;

5. Eastern Cooperative Oncology Group(ECOG)performance status 0 or 1;

6. Blood routine test and Biochemical tests:

• Hemoglobin = 80g / L;

• Absolute neutrophil count (ANC) = 1.5 × 109 / L;

• Platelet count= 90 × 109 / L;

• Alanine aminotransferase (ALT)and Aspartate aminotransferase (AST) <2.5× upper limit of normal (ULN); liver metastases, if any, the ALT and AST<5 × ULN;

• Serum total bilirubin=1.5 × ULN;

• Serum creatinine=1.5 × ULN;

• Serum albumin=30g/L;

7. Life expectancy more than 3 months;

8. Voluntarily join the study and sign the Informed Consent Form for the study;

9. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug.

Exclusion Criteria:

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to apatinib or its accessories;

2. Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class?; ?-level arrhythmia (including QT interval prolongation, for man = 450 ms, for woman = 470 ms) together with Class ?cardiac dysfunction; Patients with positive urinary protein;

3. Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);

4. Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or haematemesis in the past 2 months;primary lesion in stomach with positive fecal occult blood test (+) should be evaluated by endoscopy and other potential massive haemorrhage conditions evaluated by the investigator;

5. Abnormal Coagulation (international normalized ratio>1.5, activated partial thromboplastin time>1.5 UNL), with tendency of bleeding;

6. Associated with central nervous system (CNS) metastases;

7. Pregnant or lactating women;

8. Suffering from other malignancies within 5 years;

9. History of uncontrolled psychotropic drug abuse or mental disorders;

10. Participated in other clinical study within 4 weeks;

11. Prior VEGFR inhibitor treatment,such as sorafenib and sunitinib ;

12. Concomitant disease conditions judged by investigator that may seriously affect subject's safety or affect the study completion;

13. Other cases that the researcher found ineligible

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Gastric Cancer
• Stomach Neoplasms

Intervention

Drug:
• apatinib
Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.

Locations

Country	Name	City	State
China	307 Hospital of PLA	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.	1 year	No
Secondary	disease control rate(DCR)	Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1(RECIST1.1)	1year	No
Secondary	Objective tumor response rate(ORR)	ORR is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments.	1year	No
Secondary	overall survival(OS)	OS is defined as the length of time from random assignment to death or to last contact.	3year	No
Secondary	Quality of life score (QoL)	QoL is a questionnaire developed to assess the quality of life of cancer patients.	1year	No
Secondary	Adverse Events(AEs)	AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v4.0.	1year	Yes